118 related articles for article (PubMed ID: 26310713)
1. Mechanistic model and analysis of doxorubicin release from liposomal formulations.
Fugit KD; Xiang TX; Choi du H; Kangarlou S; Csuhai E; Bummer PM; Anderson BD
J Control Release; 2015 Nov; 217():82-91. PubMed ID: 26310713
[TBL] [Abstract][Full Text] [Related]
2. Determination of key parameters for a mechanism-based model to predict Doxorubicin release from actively loaded liposomes.
Csuhai E; Kangarlou S; Xiang TX; Ponta A; Bummer P; Choi D; Anderson BD
J Pharm Sci; 2015 Mar; 104(3):1087-98. PubMed ID: 25561354
[TBL] [Abstract][Full Text] [Related]
3. Development of a Flow-Through USP-4 Apparatus Drug Release Assay to Evaluate Doxorubicin Liposomes.
Yuan W; Kuai R; Dai Z; Yuan Y; Zheng N; Jiang W; Noble C; Hayes M; Szoka FC; Schwendeman A
AAPS J; 2017 Jan; 19(1):150-160. PubMed ID: 27485642
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination.
Fonseca NA; Gomes-da-Silva LC; Moura V; Simões S; Moreira JN
J Control Release; 2014 Dec; 196():122-31. PubMed ID: 25305563
[TBL] [Abstract][Full Text] [Related]
5. Investigation of factors affecting in vitro doxorubicin release from PEGylated liposomal doxorubicin for the development of in vitro release testing conditions.
Shibata H; Izutsu K; Yomota C; Okuda H; Goda Y
Drug Dev Ind Pharm; 2015; 41(8):1376-86. PubMed ID: 25170659
[TBL] [Abstract][Full Text] [Related]
6. Leakage kinetics of the liposomal chemotherapeutic agent Doxil: The role of dissolution, protonation, and passive transport, and implications for mechanism of action.
Russell LM; Hultz M; Searson PC
J Control Release; 2018 Jan; 269():171-176. PubMed ID: 29122661
[TBL] [Abstract][Full Text] [Related]
7. Development of pH-sensitive liposomes that efficiently retain encapsulated doxorubicin (DXR) in blood.
Ishida T; Okada Y; Kobayashi T; Kiwada H
Int J Pharm; 2006 Feb; 309(1-2):94-100. PubMed ID: 16364578
[TBL] [Abstract][Full Text] [Related]
8. An Automated Electroanalytical Method for the Drug Release Profiling of Liposomal Doxorubicin HCl Formulations.
Yurtsever F; Jiang W; Mudalige T
J Pharm Sci; 2024 Mar; 113(3):791-797. PubMed ID: 38072115
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Physicochemical Properties of Generic Doxorubicin HCl Liposome Injection with the Reference Listed Drug.
Maiti K; Bhowmick S; Jain P; Zope M; Doshi K; Rajamannar T
Anticancer Agents Med Chem; 2018; 18(4):597-609. PubMed ID: 29173186
[TBL] [Abstract][Full Text] [Related]
10. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
[TBL] [Abstract][Full Text] [Related]
11. Pharmaceutical and biomedical differences between micellar doxorubicin (NK911) and liposomal doxorubicin (Doxil).
Tsukioka Y; Matsumura Y; Hamaguchi T; Koike H; Moriyasu F; Kakizoe T
Jpn J Cancer Res; 2002 Oct; 93(10):1145-53. PubMed ID: 12417045
[TBL] [Abstract][Full Text] [Related]
12. Ion-Pairing Contribution to the Liposomal Transport of Topotecan as Revealed by Mechanistic Modeling.
Fugit KD; Anderson BD
J Pharm Sci; 2017 Apr; 106(4):1149-1161. PubMed ID: 28007561
[TBL] [Abstract][Full Text] [Related]
13. Electrosprayed Myocet-like Liposomes: An Alternative to Traditional Liposome Production.
Collier MA; Bachelder EM; Ainslie KM
Pharm Res; 2017 Feb; 34(2):419-426. PubMed ID: 27896588
[TBL] [Abstract][Full Text] [Related]
14. Predicting drug release kinetics from nanocarriers inside dialysis bags.
Yu M; Yuan W; Li D; Schwendeman A; Schwendeman SP
J Control Release; 2019 Dec; 315():23-30. PubMed ID: 31629038
[TBL] [Abstract][Full Text] [Related]
15. Effects of lipid composition on the properties of doxorubicin-loaded liposomes.
Sakai-Kato K; Nanjo K; Kawanishi T; Okuda H; Goda Y
Ther Deliv; 2015 Jul; 6(7):785-94. PubMed ID: 26228772
[TBL] [Abstract][Full Text] [Related]
16. In vitro experiments showing enhanced release of doxorubicin from Doxil® in the presence of ammonia may explain drug release at tumor site.
Silverman L; Barenholz Y
Nanomedicine; 2015 Oct; 11(7):1841-50. PubMed ID: 26115641
[TBL] [Abstract][Full Text] [Related]
17. Effect of the concentration process on unloaded and doxorubicin loaded liposomal dispersions.
Perinelli DR; Cespi M; Rendina F; Bonacucina G; Palmieri GF
Int J Pharm; 2019 Apr; 560():385-393. PubMed ID: 30802548
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
[TBL] [Abstract][Full Text] [Related]
19. Rapid Analysis of DOXIL Stability and Drug Release from DOXIL by HPLC Using a Glycidyl Methacrylate-Coated Monolithic Column.
Kimoto A; Watanabe A; Yamamoto E; Higashi T; Kato M
Chem Pharm Bull (Tokyo); 2017; 65(10):945-949. PubMed ID: 28966279
[TBL] [Abstract][Full Text] [Related]
20. An integrated assessment of morphology, size, and complement activation of the PEGylated liposomal doxorubicin products Doxil®, Caelyx®, DOXOrubicin, and SinaDoxosome.
Wibroe PP; Ahmadvand D; Oghabian MA; Yaghmur A; Moghimi SM
J Control Release; 2016 Jan; 221():1-8. PubMed ID: 26608877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
